Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/29/2025

Medical Necessity and Standard of Care Assessment for Myasthenia Gravis

Introduction to Myasthenia Gravis Management

  • The American Academy of Neurology explicitly recommends against using IVIG for chronic maintenance therapy in myasthenia gravis, with strong evidence supporting this restriction 1
  • IVIG is reserved exclusively for acute exacerbations (Grade 3-4) or myasthenic crisis situations requiring hospitalization, administered as a one-time dose of 2 g/kg over 5 days (0.4 g/kg/day × 5 days) 2, 1

Indications for IVIG

  • IVIG is only indicated for acute myasthenic crisis with respiratory compromise requiring ICU-level monitoring 2, 1
  • IVIG is only indicated for Grade 3-4 exacerbations with severe generalized weakness, limiting self-care, dysphagia, facial weakness, or rapidly progressive symptoms 2, 1
  • IVIG is only indicated for symptomatic patients resistant to or intolerant of immunosuppressive therapy during acute worsening 1

Standard of Care for Myasthenia Gravis

  • The American Academy of Neurology recommends pyridostigmine (Mestinon) starting at 30 mg orally three times daily, titrating to maximum 120 mg four times daily based on symptoms and tolerability 2, 1, 3
  • Corticosteroids (prednisone 1-1.5 mg/kg daily) are recommended for symptomatic patients with Grade 2 or higher symptoms, with gradual tapering based on improvement 2, 1
  • Azathioprine is recommended as adjunctive therapy with corticosteroids for moderate to severe disease 3

Critical Management Algorithm

  • Ensure pyridostigmine is optimally dosed (up to 120 mg four times daily if tolerated) 1
  • Initiate or optimize corticosteroids (prednisone 1-1.5 mg/kg daily) with slow taper based on response 1
  • Use IVIG 2 g/kg over 5 days ONLY if patient develops myasthenic crisis with respiratory compromise 2, 1

Monitoring Requirements

  • Pulmonary function testing (negative inspiratory force, vital capacity) is recommended given significant bulbar and proximal weakness 2, 1, 3
  • Daily neurologic assessments are recommended during any acute worsening 2
  • Regular neurology follow-up is recommended to adjust immunosuppression 1
  • Strict avoidance of contraindicated medications (β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, macrolides) is recommended 1, 3, 4

REFERENCES

1

Myasthenia Gravis Management Guidelines [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3

Diagnostic Criteria and Treatment Options for Myasthenia Gravis (MG) [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

4

Safety of Firocet in Patients with Myasthenia Gravis [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025